Clinical trials: Metastatic Non Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer
The combination of immune checkpoint inhibitors (ICI) and local ablative radiotherapy has been demonstrated to be able to increase the survival of patients with metastatic driven-genes negative non-small cell lung cancer.
- Trial name
- NCT05348668
- Testing
- Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Anhui Provincial Hospital
EGFR Overexpression, Locally Advanced Solid Tumor
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can…
- Conditions
- EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT06975410
- Testing
- YH32364
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Yuhan Corporation
Lung Cancer
Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004159
- Testing
- gemcitabine hydrochloride, paclitaxel
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Alabama at Birmingham
Metastatic Non-Small Cell Lung Cancer
A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases
This is a randomized, Phase II study designed to investigate Nimotuzumab plus whole-brain radiation therapy (WBRT)and to compare it rith WBRT alone in patients with brain metastases from non-small cell lung cancer (NSCLC).
- Trial name
- NCT00872482
- Testing
- nimotuzumab
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 21 people
- Sponsor
- YM BioSciences
Lung Cancer
Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants
RATIONALE: Fluorine F 18 FEQA may be an effective radioactive drug to use with positron emission tomography (PET) scans. PURPOSE: This clinical trial is studying the use of fluorine F 18 FEQA in patients with stage III or stage…
- Trial name
- NCT00444223
- Testing
- fluorine F 18 FEQA + positron emission tomography
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Jonsson Comprehensive Cancer Center
Locally Advanced Non-Small Cell Lung Cancer, Metastatic NSCLC
Patient's Whole Process Follow-up Management(HOPE-1)
Our project is going to explore whether management and follow-up of locally advanced/metastatic patients using the patient process management platform can prolong patient survival and improve patient quality of life.
- Trial name
- HOPE-1 (NCT05339568)
- Testing
- Patients' whole process follow-up and management platform
- Where
- China
- Volunteers
- 1,268 people
- Sponsor
- Qianfoshan Hospital
Non-squamous Cell Non-small Cell Lung Cancer
To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer
To evaluate the safety, efficacy and immunogenicity of SCT510 combined with paclitaxel and carboplatin compared with bevacizumab combined with paclitaxel and carboplatin in the first-line treatment of locally advanced metastatic…
- Trial name
- NCT03792074
- Testing
- SCT510, Bevacizumab, Paclitaxel
- Volunteers
- 560 people
- Sponsor
- Sinocelltech Ltd.
Non-Small Cell Lung Cancer, NSCLC
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
Evaluate frequency of adverse events that lead to chemotherapy discontinuation in vulnerable older adults with recurrent/metastatic PD-L1 TPS<50% NSCLC patients who receive reduced dose chemotherapy in combination with…
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, Advanced Non-Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
- Trial name
- NCT06731413
- Testing
- Reduced Dose of Chemotherapy and Immunotherapy
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Virginia Commonwealth University
Non Small Cell Lung Cancer, BRAF V600E
ENCOrafenib With Binimetinib in bRAF NSCLC
A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
- Trial name
- ENCO-BRAF (NCT04526782)
- Testing
- Encorafenib 75 MG, Binimetinib 15 MG
- Where
- 36 sites in France
- Volunteers
- 119 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced…
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
- Trial name
- KontRASt-01 (NCT04699188)
- Testing
- JDQ443, TNO155, tislelizumab
- Where
- 38 sites in United States, Australia and 14 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung, Surgery
Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery
Surgical resection is the first choice treatment for patients with non-small-cell lung cancer. Despite of advances in surgical techniques, the long-term survival rate of postoperative patient is far from optimal.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Surgery, Dexamethasone, Flubiprofen Axetil
- Trial name
- NCT03172988
- Testing
- Dexamethasone, Normal saline, Flurbiprofen axetil
- Where
- 2 sites in China
- Volunteers
- 126 people
- Sponsor
- Peking University First Hospital
Carcinoma, Non-Small-Cell Lung
Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer
A multicenter randomized phase II study evaluating the activity and tolerability of three different combinations of docetaxel (taxotere) and irinotecan (campto) as second line therapy for recurrent or metastatic non small cell…
- Trial name
- NCT00139711
- Testing
- Irinotecan, Docetaxel
- Where
- 15 sites in Italy
- Volunteers
- 138 people
- Sponsor
- Pfizer
Lung Cancer
Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, gemcitabine, docetaxel, paclitaxel, and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00079287
- Testing
- carboplatin, docetaxel, gemcitabine hydrochloride
- Where
- 24 sites in Japan
- Sponsor
- Japan Multinational Trial Organization
Lung Cancer
S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003587
- Testing
- carboplatin, cisplatin, docetaxel
- Where
- 84 sites in United States
- Volunteers
- 204 people
- Sponsor
- SWOG Cancer Research Network
Non Small Cell Lung Carcinoma NSCLC
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of…
- Trial name
- NEPTUNE (NCT02542293)
- Testing
- Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Gemcitabine + cisplatin
- Where
- 210 sites in United States, Argentina and 27 more
- Volunteers
- 953 people
- Sponsor
- AstraZeneca
Breast Cancer, Lung Cancer
Abraxane and Alimta in Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00470548
- Testing
- Abraxane, Alimta
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of California, Davis
Non-small Cell Lung Cancer
A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
To assess the efficacy and safety of Almonertinib versus platinum-based chemotherapy as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutation.
- Trial name
- NCT04951648
- Testing
- Almonertinib, chemotherapy
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
NSCLC, Non-small Cell Lung Cancer
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with…
- Conditions
- NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer
- Trial name
- RASolve 308 (NCT07777822)
- Testing
- zoldonrasib, pembrolizumab, pemetrexed + cisplatin /carboplatin
- Where
- United States
- Volunteers
- 430 people
- Sponsor
- Revolution Medicines, Inc.
Non-small Cell Lung Cancer Stage I
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS
CtDNA detection is a noninvasive detection method, and the second generation of high-throughput gene sequencing (NGS) is an important means of detecting ctDNA, which can detect trace ctDNA from smaller plasma samples.
- Trial name
- NCT03172156
- Testing
- ctDNA detection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
ALK Positive Non-small Cell Lung Cancer
Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC
This investigator-initiated, open-label, prospective Phase II clinical trial, planned to take place across multiple centers in China.
- Trial name
- NCT07750704
- Testing
- Lorlatinib, sacituzumab tirumotecan plus lorlatinib
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Guangdong Association of Clinical Trials